ICICI Direct Places Buy Call On This Mid Cap Pharma Stock, Sees 23% Potential Upside
Leading brokerage firm ICICI Direct in its recent report has placed a "buy" call on Syngene International Limited for a target price of Rs 710 per share. The brokerage sees a potential upside of 23% from its current level considering the ...